[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$fx0id4qokb1vv":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":27,"available_strengths":43,"label_statements":55,"drug_classes":82,"specialties":88,"medical_conditions":89,"animal_species":90},1780,"gf3dsw6nw4b5m289mhl02qfr","pregabalin",null,[],[13,19,23],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients",{"source":24,"licence":25,"source_url":26,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[28,34,39],{"id":29,"dose_text":30,"species":31,"administration_route":32,"limitation":10,"source_label":33},12889,"Administer orally as a single dose of 5 mg\u002Fkg (0.1 mL\u002Fkg) approximately 1.5 hours before the start of the transportation or veterinary visit.","Cats","Oral","Bonqat®",{"id":35,"dose_text":36,"species":37,"administration_route":32,"limitation":10,"source_label":38},12890,"Administer chewable tablets at 5-10 mg\u002Fkg orally twice daily with food. The 90 mg tablet is scored and may be split in half along the break-line. The 30 mg and 180 mg tablets should not be split.","Dogs","LIAVIUM™-CA1",{"id":40,"dose_text":41,"species":10,"administration_route":42,"limitation":10,"source_label":33},12891,"Client Information Sheet is on the reverse of this package insert.\nAlways provide client information sheet with prescription.\nBONQAT is administered orally as a single dose of 5 mg\u002Fkg (0.1 mL\u002Fkg) approximately 1.5 hours before the start of the transportation or veterinary visit and can be given on two consecutive days.\nIf the cat weighs more than 22 pounds, the total dose will need to be calculated and given in two separate doses as the syringe holds a maximum of 1 mL of solution.\nA small amount of food can be given with BONQAT.","ORAL",[44,48,52],{"id":45,"strength_text":46,"dosage_form":47,"proprietary_name":33,"species":31,"source_label":33},11175,"Each mL contains 50 mg pregabalin","Oral Solution",{"id":49,"strength_text":50,"dosage_form":51,"proprietary_name":38,"species":37,"source_label":38},11176,"Each chewable tablet contains 30 milligrams (mg), 90 mg, or 180 mg of pregabalin.","Chewable Tablets",{"id":53,"strength_text":54,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":33},11177,"50 mg \u002F 1 mL",[56,60,63,66,70,74,78],{"id":57,"kind":58,"statement":59,"species":31,"limitation":10,"source_label":33},18853,"indication","For alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.",{"id":61,"kind":58,"statement":62,"species":37,"limitation":10,"source_label":38},18854,"LIAVIUM™-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs.",{"id":64,"kind":58,"statement":65,"species":10,"limitation":10,"source_label":33},18855,"BONQAT is indicated for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.",{"id":67,"kind":68,"statement":69,"species":10,"limitation":10,"source_label":33},18856,"contraindication","Do not use in case of hypersensitivity to pregabalin or to any of the excipients (sodium benzoate, ethyl maltol, hydrochloric acid, sodium hydroxide).",{"id":71,"kind":72,"statement":73,"species":10,"limitation":10,"source_label":33},18857,"warning","Human Safety Warnings:\nNot for human use.\nAppropriate precautions should be taken while handling BONQAT. Avoid skin contact, eye contact, or contact with mucous membranes.\nSymptoms of exposure to pregabalin include dizziness, sleepiness, blurred vision, weakness, dry mouth, and difficulty with concentration or attention.\nIn case of accidental eye or mucosal exposure, flush with water for 15 minutes. If wearing contact lenses, eyes should be rinsed first, then remove contact lenses and continue rinsing. Seek medical advice if symptoms occur.\nIn case of skin contact, wash with soap and water immediately. Remove contaminated clothing. Seek medical advice if symptoms occur.\nIn case of accidental ingestion, seek medical advice if symptoms occur. Do not drive as sleepiness may occur. In case of ingestion by a child, seek medical attention immediately. Show the package insert or the label to the physician.\nDrug Abuse, Addiction, and Diversion\nControlled Substance:\nBONQAT contains pregabalin, a Schedule V controlled substance.\nAbuse: Abuse is defined as the intentional, non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Pregabalin is not known to be active at receptor sites associated with drugs of abuse. However, pregabalin is associated with drug liking and is known to be misused and abused in the community, particularly in combination with opioids. Consider the potential risks of misuse or abuse before prescribing this product. Signs of pregabalin misuse or abuse include drug seeking behavior.\nPregabalin should be handled appropriately to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the clinical setting and as required by law.\nNote to physician: BONQAT contains pregabalin.\nThe safety data sheet (SDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the SDS for BONQAT contact Zoetis Inc. at 1-888-963-8471.\nAnimal Safety Warnings: Some cats may experience hypothermia, depression, drowsiness, muscle tremors, and\u002For ataxia. These cats should be kept warm and not offered food or water until BONQAT’s effects have worn off (usually within 6 hours). (See TARGET ANIMAL SAFETY)\nKeep BONQAT in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.",{"id":75,"kind":76,"statement":77,"species":10,"limitation":10,"source_label":33},18858,"adverse_reaction","In a well-controlled European field study, which included a total of 238 cats (108 treated with BONQAT at the label dose of 5 mg\u002Fkg, 29 treated with BONQAT at a dose of 2.5 mg\u002Fkg, and 101 administered placebo control), 5 months to 15 years of age and weighing 1.8 to 10.3 kg, the following adverse reactions were reported:\nTable 1. Adverse reactions\nAdverse reaction\nPregabalin\n5 mg\u002Fkg\nN=108\nPregabalin\n2.5 mg\u002Fkg\nN=29\nPlacebo\nN=101\nAtaxia\n5 (4.6%)\n1 (3.4%)\n0\nLethargy\n3 (2.8%)\n2 (6.9%)\n0\nEmesis\n2 (1.9%)\n0\n0\nProprioception abnormality\n1 (0.9%)\n1 (3.4%)\n0\nMuscle tremor\n1 (0.9%)\n0\n0\nAnorexia\n1 (0.9%)\n0\n0\nWeight loss\n1 (0.9%)\n0\n0\nMydriasis\n0\n1 (3.4%)\n0",{"id":79,"kind":80,"statement":81,"species":10,"limitation":10,"source_label":33},18859,"mechanism_of_action","Absorption\nBONQAT is rapidly absorbed after oral administration in cats. Following oral administration of 5 mg\u002Fkg to fasted cats the maximum observed concentration (Cmax) in plasma was 10.1 ± 0.8 (SD) μg\u002FmL and occurred at 0.5-1.0 hours post-dose. The area under plasma concentration time curve from time zero to the last quantifiable time point (AUClast) was 199±27 μg*h\u002FmL. The mean absolute oral bioavailability was 94.3%.\nDistribution\nBONQAT has a relatively large volume of distribution. After intravenous (IV) bolus administration of 2.5 mg\u002Fkg, the volume of distribution at the steady state (Vss) was 0.4±0.02 L\u002Fkg in cats. BONQAT is not known to bind to plasma proteins in other species, but this has not been studied in cats.\nMetabolism and excretion\nBONQAT is slowly eliminated from the body of cats. After IV bolus administration of 2.5 mg\u002Fkg, total plasma clearance was 0.03±0.008 L\u002Fh\u002Fkg. The mean half-life of elimination from circulation was 12.3±3.1 hours after IV administration of 2.5 mg\u002Fkg and 14.7±2.7 hours after oral administration of 5 mg\u002Fkg.\nElimination of the parent compound as well as the methylation metabolite from circulation occurs almost exclusively by renal excretion in other species. This has not been studied in cats.\nMechanism of Action\nPregabalin is a ligand of alpha2-delta subunit of voltage-gated calcium channels. It reduces the presynaptic calcium influx in neurons and thereby the release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, substance P and calcitonin gene-related peptide.",[83],{"id":84,"documentId":85,"slug":86,"name":87},835,"t9tj6uzjddax6el3zphd9j5y","unknown-cellular-or-molecular-interaction","Unknown Cellular or Molecular Interaction",[],[],[]]